ValiRx PLC Total Voting Rights and Block Listing Update
RNS Number : 6160A
01 October 2020
("ValiRx", the "Company" or the "Group")
Total Voting Rights and Block Listing Update
London, UK 1 October 2020: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company today updated its total voting rights
In conformity with DTR 5.6.1, the Company notifies that as at
the date of this announcement, the total number of Ordinary Shares
in issue will be 63,928,325. There are no Ordinary Shares held in
treasury. Each Ordinary Share entitles the holder to a single vote
at general meetings of the Company.
The figure of 63,928,325 Ordinary Shares may be used by
shareholders (and others with notification obligations) as the
denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
As announced on 29 September 2020, application has been made to
the London Stock Exchange to admit the 60,000 new ordinary shares
resulting from the Warrant Exercise to trading on AIM. Admission of
the new ordinary shares is expected to occur on or around 2 October
2020. The new ordinary shares will rank pari passu with the
existing ordinary shares.
Following admission of the 60,000 new ordinary shares to trading
on AIM on or around 2 October 2020, the Company's total issued
share capital will comprise 63,988,325 ordinary shares of 0.1 pence
As at the date of this announcement, 7,930,568 warrants at 13p
have been exercised bringing gross proceeds of circa GBP1,030,000
(of which circa GBP668,000 were received in September 2020) to the
Company and 1,104,164 warrants exercisable at 13p are outstanding.
The aggregate number of warrants exercised at 13p in the month of
October 2020 (and subject to the block listing announced on 19
August 2020) will be notified in the monthly total voting rights
update on 2 November 2020.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc Tel: +44 (0) 20 7073
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
Optimum Strategic Communications Tel: +44 (0) 20 8148
Supriya Mathur/ Shabnam Bashir 3040
ValiRx accelerates the development of treatments in oncology
and women's health to improve patient lives. We provide the
scientific, financial and commercial framework to enable rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development,
from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical
and commercial domains, with the promise of achieving a more
streamlined, less costly, drug development process. We work
closely with our selected collaborators and leverage the combined
expertise required for science to advance.
Lead candidates from our portfolio are out-licenced or partnered
with investors through ValiRx subsidiary companies for further
clinical development and commercialisation. https://www.valirx.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
October 01, 2020 02:00 ET (06:00 GMT)
Historical Stock Chart
From Dec 2020 to Jan 2021
Historical Stock Chart
From Jan 2020 to Jan 2021